Siemionow M, Zielinski M, Ozmen S, Izycki D
Department of Plastic Surgery A-60, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Transplant Proc. 2005 Jun;37(5):2303-8. doi: 10.1016/j.transproceed.2005.03.127.
We investigated the effect of the intraosseous allotransplantation of the donor-derived hematopoietic stem cells (HSC) CD90+ on chimerism induction and survival of rat hind limb transplants. Eighteen rat hind limb transplantations were performed between Lewis-Brown-Norway and Lewis rats in three groups. Isograft and allograft rejection controls received no treatment. In the experimental group, 0.8 to 1.2 x 10(6) of separated and purified CD90+ HSC cells were transplanted intramedullary into the bone marrow cavity of the recipient's tibia during opposite hind limb transplantation, without immunosuppressive therapy. Transplants from isograft group survived indefinitely. Allograft controls rejected transplants on day 7 posttransplant. The injection of separated and purified CD90+ cells of the donor origin extended survival of the transplanted limbs up to 15 days in group III. We introduced a novel method of transplantation of the CD90+ cells of the donor origin into the recipient's bone marrow cavity. This technique resulted in extended allograft survival, without immunosuppressive therapy.
我们研究了供体来源的造血干细胞(HSC)CD90+进行骨内同种异体移植对大鼠后肢移植嵌合现象诱导及存活情况的影响。在Lewis-Brown-Norway大鼠和Lewis大鼠之间进行了三组共18例大鼠后肢移植。同基因移植和同种异体移植排斥对照组未接受任何治疗。在实验组中,在对侧后肢移植过程中,将0.8至1.2×10⁶个分离纯化的CD90+HSC细胞经骨髓腔内注射到受体胫骨中,未进行免疫抑制治疗。同基因移植组的移植肢体永久存活。同种异体移植对照组在移植后第7天排斥移植肢体。在第三组中,注射供体来源的分离纯化CD90+细胞可使移植肢体的存活期延长至15天。我们引入了一种将供体来源的CD90+细胞移植到受体骨髓腔的新方法。该技术在未进行免疫抑制治疗的情况下延长了同种异体移植的存活时间。